The acceptability and feasibility of peer worker support role in community based HCV treatment for injecting drug users.

作者: Josephine Norman , Nick M Walsh , Janette Mugavin , Mark A Stoové , Jenny Kelsall

DOI: 10.1186/1477-7517-5-8

关键词: PsychosocialDrugSocial workHealth psychologyHepatitis CSocial policyAlternative medicineMental healthMedicinePsychiatry

摘要: Hepatitis C is the most common blood borne virus in Australia affecting over 200 000 people. Effective treatment for hepatitis has only become accessible since late 1990's, although active injecting drug use (IDU) remained an exclusion criteria government-funded until 2001. Treatment uptake been slow, particularly among users, largest affected group. We developed a peer-based integrated model of care at community and alcohol clinic. Clients interested eligible had their substance use, mental health other psychosocial comorbidities co-managed onsite clinic prior to during treatment. In qualitative preliminary evaluation project, nine current patients were interviewed, as was peer worker. A high level patient acceptability endorsement found. This paper describes by clients using service.

参考文章(30)
Mary E. Larimer, G. Alan Marlatt, Katie Witkiewitz, Harm Reduction: Pragmatic Strategies for Managing High-Risk Behaviors ,(2002)
Margaret A MacDonald, John M Kaldor, Alex D Wodak, Kate A Dolan, Ingrid Beek, Philip H Cunningham, Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995-1997. The Medical Journal of Australia. ,vol. 172, pp. 57- 61 ,(2000) , 10.5694/J.1326-5377.2000.TB139199.X
Lucas Wiessing, Mirjam Kretzschmar, Maarten Postma, Johannes Jager, Wien Limburg, Hepatitis C and injecting drug use: impact, costs and policy options. EMCDDA scientific monographs series. ,vol. 7, ,(2004)
Maxime Cournot, André Glibert, Fabienne Castel, François Druart, Kamran Imani, Valérie Lauwers-Cances, Thierry Morin, Management of hepatitis C in active drugs users: experience of an addiction care hepatology unit. Gastroenterologie Clinique Et Biologique. ,vol. 28, pp. 533- 539 ,(2004) , 10.1016/S0399-8320(04)95008-7
John Farley, Shawn Vasdev, Benedikt Fischer, Jürgen Rehm, Emma Haydon, Hepatitis C treatment in a Canadian federal correctional population: Preliminary feasibility and outcomes International Journal of Prisoner Health. ,vol. 1, pp. 13- 18 ,(2005) , 10.1080/17449200500157044
Martin Schaefer, Andreas Heinz, Markus Backmund, Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? Addiction. ,vol. 99, pp. 1167- 1175 ,(2004) , 10.1111/J.1360-0443.2004.00821.X
VGSJ Soriano, J Garcia-Samaniego, R Bravo, J Gonzalez, A Castro, J Castilla, P Martinez-Odriozola, M Colmenero, E Carballo, D Suarez, FJ Rodriguez-Pinero, A Moreno, J del Romero, J Pedreira, J Gonzalez-Lahoz, None, Interferon α for the Treatment of Chronic Hepatitis C in Patients Infected with Human Immunodeficiency Virus Clinical Infectious Diseases. ,vol. 23, pp. 585- 591 ,(1996) , 10.1093/CLINIDS/23.3.585
SL Jowett, K Agarwal, BC Smith, W Craig, M Hewett, DR Bassendine, E Gilvarry, AD Burt, MF Bassendine, Managing chronic hepatitis C acquired through intravenous drug use. QJM: An International Journal of Medicine. ,vol. 94, pp. 153- 158 ,(2001) , 10.1093/QJMED/94.3.153
N Crofts, D Jolley, J Kaldor, I van Beek, A Wodak, Epidemiology of hepatitis C virus infection among injecting drug users in Australia. Journal of Epidemiology and Community Health. ,vol. 51, pp. 692- 697 ,(1997) , 10.1136/JECH.51.6.692